A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.
Cancer 117(10):2050-7 (2011) PMID 21523716
The purpose of this study was to compare 2 weekly docetaxel-based regimens as first-line treatments for advanced gastric cancer and to investigate the expression of secreted protein acidic and rich in cysteine (SPARC) and its abilities to predict treatment-related clinical outcomes.
DOI: 10.1002/cncr.25729
Version: za2963e q8za3 q8zba q8zc0 q8zd3 q8ze0 q8zff q8zg1